Recombinant Human HSP27 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human HSP27 protein (rFc Tag) (Eg4620)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg4620

---

Validation Data Gallery

• 

  Purity of Recombinant Human HSP27 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human HSP27 protein Ala70-Thr184 (Accession# P04792) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 3315
• Accession: P04792
• PredictedSize: 39.0 kDa
• SDS-PAGE: 40-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Heat shock protein 27 (HSP27), also known as HSPB1, belongs to the small heat shock protein family which is induced in response to environmental challenges or/and developmental transitions. It is also an anti-apoptotic protein that plays crucial roles in tumorigenesis and cell survival and is reported to be an independent prognosis marker for cancer. Recently HSP27 has been found to be a valuable marker for melanoma.

References:

1. Kijima K. et al. (2005). J Hum Genet. 50(9):473-476.
2. Foster CS. et al.(2009). Br J Cancer. 101(7):1137-44.
3. Okuno M. et al. (2016). Int J Mol Sci. 17(1):137.
4. Seo MK. et al. (2020). Pharmacoecon Open. 4(3):529-539.